GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) » Definitions » Debt-to-EBITDA

Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2009. Start your Free Trial

What is Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmedic Pharmaceutical Medicinal Joint Stock Company's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Pharmedic Pharmaceutical Medicinal Joint Stock Company's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized EBITDA for the quarter that ended in . 20 was ₫0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA or its related term are showing as below:

HSTC:PMC's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Historical Data

The historical data trend for Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Chart

Pharmedic Pharmaceutical Medicinal Joint Stock Company Annual Data
Trend
Debt-to-EBITDA

Pharmedic Pharmaceutical Medicinal Joint Stock Company Quarterly Data
Debt-to-EBITDA

Competitive Comparison of Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA falls into.



Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.


Pharmedic Pharmaceutical Medicinal Joint Stock Company  (HSTC:PMC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) Business Description

Traded in Other Exchanges
N/A
Address
367 Nguyen Trai, Nguyen Cu Trinh Ward, District 1, TP. HCM, Ho Chi Minh, VNM
Pharmedic Pharmaceutical Medicinal Joint Stock Company is involved in the production and sales of pharmaceutical products, pharmaceuticals, cosmetics, medical supplies, and other products in the health sector.

Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) Headlines

From GuruFocus

PharMerica Corp. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010

Weekly CFO Buys Highlight: PMC, ZBB

By gurujk gurujk 06-25-2012

PharMerica Corp. (PMC) CEO Gregory S Weishar buys 81,000 Shares

By GuruFocus Research GuruFocus Editor 08-13-2010

PharMerica Corp. (PMC) CEO Gregory S Weishar buys 25,000 Shares

By GuruFocus Research GuruFocus Editor 11-16-2009

PharMerica Corp. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010